Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVB-S6-500 in IgA Nephropathy
NCT04042623Phase 2Terminated
- Sponsor
- Aravive, Inc.
- Start
- Nov 2019
- Primary completion
- Aug 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of batiraxcept in IgA nephropathy (IgAN), sponsored by Aravive, Inc.. Started Nov 2019; status: terminated.
02
Drugs
batiraxcept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT04042623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04042623.